Achieving a Successful Scale-Down Model and Optimized Economics through Parvovirus Filter Validation using Purified TrueSpike^TM Viruses

References

1. 1.↵
   PDA Technical Report No. 47: Preparation of Virus Spikes Used for Virus Clearance Studies. Parenteral Drug Association: Bethesda, MD, 2010.
2. 2.↵
   FDA; ICH. Guidance for Industry. Q5A Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. U.S. Department of Health and Human Services, FDA, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research: Rockville, MD, 1998.
3. 3.↵
   The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Unit, Committee for Proprietary Medicinal Products (CPMP). Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products, 2009. CPMP/BWP/398498/2005.
4. 4.↵
   PDA Technical Report No. 41: Virus Filtration. Parenteral Drug Association: Bethesda, MD, 2008.
5. 5.↵
   1. Miesegaes G.,
   2. Bailey M.,
   3. Willkommen H.,
   4. Chen Q.,
   5. Roush D.,
   6. Blumel J.,
   7. Brorson K.

   Proceedings of the 2009 Viral Clearance Symposium. Dev. Biol. (Basel) 2010, 133, 3–101.

   OpenUrlPubMed
6. 6.↵
   1. Bolton G. R.,
   2. Spector S.,
   3. Lacasse D.

   Increasing the capacity of parvovirus-retentive membranes: performance of the Viresolve prefilter. Biotechnol. Appl. Biochem. 2006, 43 (Pt 1), 55–63.

   OpenUrlPubMed
7. 7.↵
   1. Brown A.,
   2. Bechtel C.,
   3. Bill J.,
   4. Liu H.,
   5. Liu J.,
   6. McDonald D.,
   7. Pai S.,
   8. Radhamohan A.,
   9. Renslow R.,
   10. Thayer B.,
   11. Yohe S.,
   12. Dowd C.

   Increasing parvovirus filter throughput of monoclonal antibodies using ion exchange membrane adsorptive pre-filtration. Biotechnol. Bioeng. 2010, 106 (4), 627–637.

   OpenUrlPubMed
8. 8.↵
   1. Genest P.,
   2. Ruppach H.,
   3. Geyer C.,
   4. Asper M.,
   5. Parrella J.,
   6. Evans B.,
   7. Slocum A.

   Artifacts of virus filter validation. BioProcess Int. 2013, 11 (5), 54–61.

   OpenUrl
9. 9.↵
   1. Cabatingan M.

   Impact of virus stock quality on virus filter validation. BioProcess Int. 2005, 3 (10), S39–S43.

   OpenUrl
10. 10.↵
    1. Slocum A.,
    2. Burnham M.,
    3. Genest P.,
    4. Venkiteshwaran A.,
    5. Chen D.,
    6. Hughes J.

    Impact of virus preparation quality on parvovirus filter performance. Biotechnol. Bioeng. 2013, 110 (1), 229–239.

    OpenUrlPubMed
11. 11.↵
    1. Asher D.,
    2. Slocum A.,
    3. Bergmann K.,
    4. Genest P.,
    5. Katz A.,
    6. Morais J.,
    7. Lawrence C.,
    8. Greenhalgh P.

    Predicting virus filtration performance with virus spike characterization. BioProcess Int. 2011, 9 (3), 26–37.

    OpenUrl
12. 12.↵
    1. Lute S.,
    2. Bailey M.,
    3. Combs J.,
    4. Sukumar M.,
    5. Brorson K.

    Phage passage after extended processing in small-virus-retentive filters. J. Biotechnol. Appl. Biochem. 2007, 47 (Pt 3), 141–151.

    OpenUrl
13. 13.↵
    1. Zachariah M. R.,
    2. Tarlov M. J.,
    3. Etzel M.,
    4. Brorson K.

    1. Lute S.,
    2. Riordan W.,
    3. Pease L. F. III.,
    4. Tsai D.-H.,
    5. Levy R.,
    6. Haque M.,
    7. Martin J.,
    8. Moroe I.,
    9. Sato T.,
    10. Morgan M.,
    11. Krishnan M.,
    12. Campbell J.,
    13. Genest P.,
    14. Dolan S.,
    15. Tarrach K.,
    16. Meyer A.

    ; PDA Virus Filter Task Force; Zachariah M. R., Tarlov M. J., Etzel M., Brorson K. A consensus rating method for small virus–retentive filters. I. Method development. PDA J. Pharm. Sci. Technol. 2008, 62 (5), 318–333.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    1. Aranha H.,
    2. Bailey M.,
    3. Bender J.,
    4. Carter J.,
    5. Chen Q.,
    6. Dowd C.,
    7. Jani R.,
    8. Jen D.,
    9. Kidd S.,
    10. Meltzer T.,
    11. Remington K.,
    12. Rice I.,
    13. Romero C.,
    14. Sato T.,
    15. Jornitz M.,
    16. Sekura C. M.,
    17. Sofer G.,
    18. Specht R.,
    19. Wojciechowski P.

    1. Brorson K.,
    2. Lute S.,
    3. Haque M.,
    4. Martin J.,
    5. Sato T.,
    6. Moroe I.,
    7. Morgan M.,
    8. Krishnan M.,
    9. Campbell J.,
    10. Genest P.,
    11. Parrella J.,
    12. Dolan S.,
    13. Martin S.,
    14. Tarrach K.,
    15. Levy R.

    ; PDA Virus Filter Task Force, Aranha H., Bailey M., Bender J., Carter J., Chen Q., Dowd C., Jani R., Jen D., Kidd S., Meltzer T., Remington K., Rice I., Romero C., Sato T., Jornitz M., Sekura C. M., Sofer G., Specht R., Wojciechowski P. A consensus rating method for small virus–retentive filters. II. Method evaluation. PDA J. Pharm. Sci. Technol. 2008, 62 (5), 334–343.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Wu Y.,
    2. Ahmed A.,
    3. Waghmare R.,
    4. Genest P.,
    5. Issacson S.,
    6. Krishnan M.,
    7. Kahn D. W.

    Validation of adventitious virus removal by virus filtration. BioProcess Int. 2008, 6 (5), 54–59.

    OpenUrl
16. 16.↵
    1. Khan N. Z.,
    2. Parrella J. J.,
    3. Genest P. W.,
    4. Colman M. S.

    Filter preconditioning enables representative scaled-down modelling of filter capacity and viral clearance by mitigating the impact of virus spike impurities. Biotechnol. Appl. Biochem. 2009, 52 (4), 293–301.

    OpenUrlPubMed
17. 17.↵
    1. Parrella J.,
    2. Wu Y.,
    3. Kahn D. W.,
    4. Genest P.

    RUNspike, a complementary virus filter spiking method: a solution to the problem of reduced throughput due to the addition of the virus spike. PDA J. Pharm. Sci. Technol. 2009, 63 (6), 547–558.

    OpenUrlAbstract/FREE Full Text
18. 18.↵
    European Patent Application number 11162488.8. Methods of Producing High Titer, High Purity Virus Stocks and Methods of Use Thereof, 2011.
19. 19.↵
    1. Spearman C.

    The method of right or wrong cases (constant stimuli) without Gauss's formulae. Br. J. Psychol. 1908, 2, 227.

    OpenUrlWeb of Science
20. 20.↵
    1. Kärber G.

    Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs Arch. Exp. Path. Pharmak. 1931, 162 (4), 480–483.

    OpenUrlCrossRef